

Kindred Biosciences Receives FDA Approval of Mirataz

07 May 2018 | News

Kindred Biosciences Receives FDA Approval of Mirataz™ (mirtazapine transdermal ointment) for the Management of Weight Loss in Cats



Kindred Biosciences, Inc. a biopharmaceutical company focused on saving and improving the lives of pets, announced that the U.S. Food and Drug Administration's Center for Veterinary Medicine approved Mirataz (mirtazapine transdermal ointment) for the management of weight loss in cats.

Mirataz is the first and only transdermal medication specifically developed, and FDA approved, for cats. Weight loss is the leading cause of visits to the veterinarian for cats. Mirataz, which is formulated with KindredBio's proprietary Accusorb™ technology, is applied topically to the cat's inner ear (pinna) once a day, providing a more attractive application route compared to oral administration. Mirataz is a serotonin (5HT_{2A}, 5HT_{2C}, and 5HT₃) and histamine (H₁) receptor antagonist, which has demonstrated body weight gain in cats experiencing weight loss. The product is classified as a weight gain drug and can be used in cats with various underlying diseases associated with unintended weight loss.